Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross Profit | $10.6B | $11.2B | $12.1B | $14.4B | $16.0B | $17.6B | $18.7B | $19.2B | $17.8B | $18.2B | $14.7B | $14.9B | $15.6B | $16.8B | $16.8B | $17.6B | $19.1B | $21.0B | $21.9B | $27.0B |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Eli Lilly and Company's last 12-month Gross Profit is $33.3B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Eli Lilly and Company's Gross Profit growth was 32.1%. The average annual Gross Profit growth rates for Eli Lilly and Company have been 19.9% over the past three years, 13.6% over the past five years.
Over the last year, Eli Lilly and Company's Gross Profit growth was 32.1%, which is higher than industry growth of 0.3%. It indicates that Eli Lilly and Company's Gross Profit growth is Good.